RecruitingPhase 2NCT07489651

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder

Sponsor

Reunion Neuroscience Inc

Enrollment

64 participants

Start Date

Apr 20, 2026

Study Type

INTERVENTIONAL

Conditions

Generalized Anxiety Disorder

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Eligibility

Min Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called RE104 for Injection for people with generalized anxiety disorder. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRE104 for Injection

Single, subcutaneous dose of RE104 for Injection

DRUGPlacebo

Single, subcutaneous dose of 0.9% sodium chloride for injection

Locations(22)

Lighthouse Psychiatry

Gilbert, Arizona, United States

Preferred Research Partners, Inc.

Little Rock, Arkansas, United States

Collaborative Neuroscience Research, LLC

Garden Grove, California, United States

Kadima Neuropsychiatry Institute

La Jolla, California, United States

Open Mind Therapeutics

San Francisco, California, United States

TRIP Clinic at Psychedelic Science Institute

Santa Monica, California, United States

Innovative Clinical Research, Inc.

Lauderhill, Florida, United States

University of South Florida

Tampa, Florida, United States

Atlanta Center for Medical Research

Atlanta, Georgia, United States

CenExel iResearch, LLC

Decatur, Georgia, United States

Uptown Research Institute

Chicago, Illinois, United States

Henry Ford Medical Center - Columbus

Novi, Michigan, United States

Midwest Research Group

Saint Charles, Missouri, United States

UNM Research Program Psychedelic Therapies

Albuquerque, New Mexico, United States

NYU-H+C Clinical and Translational Science Institute

New York, New York, United States

Neuro-Behavioral Clinical Research, Inc.

North Canton, Ohio, United States

Summit Headlands LLC

Portland, Oregon, United States

Austin Clinical Trial Partners

Austin, Texas, United States

BioBehavioral Research Austion

Austin, Texas, United States

Aim Trials, LLC

Plano, Texas, United States

Cedar Clinical Research

Draper, Utah, United States

Inner Space State Street

Orem, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07489651

Related Trials

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

NCT063767342 locations

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

NCT074787441 location